A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Stamatatos, Leonidas; Czartoski, Julie; Wan, Yu-Hsin; Homad, Leah J.; Rubin, Vanessa; Glantz, Hayley; Neradilek, Moni; Seydoux, Emilie; Jennewein, Madeleine F.; MacCamy, Anna J.; Feng, Junli; Mize, Gregory; De Rosa, Stephen C.; Finzi, Andrés; Lemos, Maria P.; Cohen, Kristen W.; Moodie, Zoe; McElrath, M. Juliana; McGuire, Andrew T.

doi:10.1101/2021.02.05.21251182

PreprintCited by 559SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinationsvaccines and immunoinformatics approaches

A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Open access

Stamatatos, Leonidas, Czartoski, Julie, Wan, Yu-Hsin, Homad, Leah J., Rubin, Vanessa, Glantz, Hayley, Neradilek, Moni, Seydoux, Emilie +11 more·2021·Science

DOI 10.1101/2021.02.05.21251182PMC PMC7987032

Preprint — published as 10.1126/science.abg9175 · Paper page

Open this paper in CoChat — free account

Abstract

Emerging SARS-CoV-2 variants have raised concerns about resistance to neutralizing antibodies elicited by previous infection or vaccination. We examined whether sera from recovered and naïve donors collected prior to, and following immunizations with existing mRNA vaccines, could neutralize the Wuhan-Hu-1 and B.1.351 variants. Pre-vaccination sera from recovered donors neutralized Wuhan-Hu-1 and sporadically neutralized B.1.351, but a single immunization boosted neutralizing titers against all variants and SARS-CoV-1 by up to 1000-fold. Neutralization was due to antibodies targeting the receptor binding domain and was not boosted by a second immunization. Immunization of naïve donors also elicited cross-neutralizing responses, but at lower titers. Our study highlights the importance of vaccinating both uninfected and previously infected persons to elicit cross-variant neutralizing antibodies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1101/2021.02.05.21251182

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Convalescent individuals who received mRNA vaccines showed an average increase of 8.6-fold in the number of circulating RBD-specific memory B cells.
“By contrast, and consistent with previous reports5,8,20, individuals who recovered from COVID-19 and received mRNA vaccines showed an average increase of 8.6-fold in the number of circulating RBD-specific memory B cells (Fig. 2a).”
From Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) · cites this paper as [20]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384 · see citing works
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244 · see citing works
The REDCap consortium: building an international community of software platform partners
Harris, P. A., Taylor, R., Minor, B. L., Elliott, V., Fernandez, M., O'Neal, L., McLeod, L., Delacqua, G., Delacqua, F., Kirby, J., et al. (2019) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2019.103208 · Cited by 24,013 · see citing works
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969 · see citing works
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286 · see citing works
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · see citing works
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688 · see citing works
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · see citing works
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048 · see citing works
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897 · see citing works
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586 · see citing works
Self-citation
Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341 · see citing works
Self-citation
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · see citing works
Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109 · see citing works
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097 · see citing works
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656 · cited 1× · see citing works
“SARS-CoV-2 infection rapidly elicits neutralizing antibody responses (16, 21-24) that decline, but remain detectable over several months (25-29).”
Background
Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · cited 4× · see citing works
“1) that harbor specific mutations in their S proteins that may be associated with increased transmissibility (50-55).”
BackgroundInfluential
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Wu, X.-L., Yang, Z.-Y., Li, Y.-X., Hogerkorp, C.-M., Schief, W., Seaman, M., Zhou, T., Schmidt, S., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,878 · see citing works
Human neutralizing antibodies elicited by SARS-CoV-2 infection
Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667 · cited 1× · see citing works
“RBD monoclonal antibodies (mAbs) have been characterized, the most potent of which block the RBD-ACE2 interaction (16, 17, 22-24, 32-37).”
Background
Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data
Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., O’Toole, Á., et al. (2021) · doi:10.1101/2020.12.30.20249034 · Cited by 1,611 · cited 1× · see citing works
“1) that harbor specific mutations in their S proteins that may be associated with increased transmissibility (50-55).”
Background
The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity
Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., Zhao, C., Zhang, Q., Liu, H., Nie, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.012 · Cited by 1,420 · see citing works
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419 · see citing works
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
Piccoli, L., Park, Y.-J., Tortorici, M. A., Czudnochowski, N., Walls, A. C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L. E., Bowen, J. E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.037 · Cited by 1,395 · see citing works
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., Yang, Y., et al. (2020) · Science · doi:10.1126/science.abc6952 · Cited by 1,385 · see citing works
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349 · see citing works
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2381-y · Cited by 1,286 · see citing works
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
Baum, A., Fulton, B. O., Wloga, E., Copin, R., Pascal, K. E., Russo, V., Giordano, S., Lanza, K., Negron, N., Ni, M., et al. (2020) · Science · doi:10.1126/science.abd0831 · Cited by 1,253 · see citing works
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.-T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020) · Science · doi:10.1126/science.abc7520 · Cited by 1,230 · cited 17× · see citing works
“In support of this, passive transfer of nAbs limits respiratory tract infection and protects against infection in animal models (16-20) and may”
BackgroundInfluential
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Hansen, J., Baum, A., Pascal, K. E., Russo, V., Giordano, S., Wloga, E., Fulton, B. O., Yan, Y., Koon, K., Patel, K., et al. (2020) · Science · doi:10.1126/science.abd0827 · Cited by 1,210 · see citing works
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells
Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.025 · Cited by 1,188 · see citing works
Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies
Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · doi:10.1101/2020.12.31.425021 · Cited by 1,178 · cited 1× · see citing works
“The majority of serum neutralizing antibody responses elicited during natural infection are directed at the RBD (21, 23, 30-32).”
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science · doi:10.1126/science.abc5902 · Cited by 1,140 · see citing works
Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques
McMahan, K., Yu, J., Mercado, N. B., Loos, C., Tostanoski, L. H., Chandrashekar, A., Liu, J., Peter, L., Atyeo, C., Zhu, A., et al. (2021) · Nature · doi:10.1038/s41586-020-03041-6 · Cited by 1,068 · see citing works
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
Wu, Y., Wang, F., Shen, C., Peng, W., Li, D., Zhao, C., Li, Z., Li, S., Bi, Y., Yang, Y., et al. (2020) · Science · doi:10.1126/science.abc2241 · Cited by 955 · see citing works
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940 · see citing works
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
McCallum, M., Marco, A. D., Lempp, F., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · doi:10.1101/2021.01.14.426475 · Cited by 901 · cited 1× · see citing works
“Neutralizing mAbs targeting epitopes on the NTD of S1 (24, 34, 38-40) and S2 have also been identified (41, 42).”
Background
SARS-CoV-2 infection protects against rechallenge in rhesus macaques
Chandrashekar, A., Liu, J., Martinot, A. J., McMahan, K., Mercado, N. B., Peter, L., Tostanoski, L. H., Yu, J., Maliga, Z., Nekorchuk, M., et al. (2020) · Science · doi:10.1126/science.abc4776 · Cited by 816 · cited 1× · see citing works
“infection in humans (9-11) and in non-human primates (12, 13).”
Background
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence
Sabino, E. C., Buss, L. F., Carvalho, M. P. S., Prete, C. A., Crispim, M. A. E., Fraiji, N. A., Pereira, R. H. M., Parag, K. V., da Silva Peixoto, P., Kraemer, M. U. G., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00183-5 · Cited by 758 · see citing works
Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays
Crawford, K. H. D., Eguia, R. T., Dingens, A. S., Loes, A. N., Malone, K. D., Wolf, C. R., Chu, H. Y., Tortorici, M. A., Veesler, D., Murphy, M., et al. (2020) · Viruses · doi:10.3390/v12050513 · Cited by 727 · see citing works
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
Thomson, E. C., Rosen, L. E., Shepherd, J. G., Spreafico, R., da Silva Filipe, A., Wojcechowskyj, J. A., Davis, C., Piccoli, L., Pascall, D. J., Dillen, J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.037 · Cited by 606 · see citing works
Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
Cerutti, G., Guo, Y., Zhou, T., Gorman, J., Lee, M., Rapp, M., Reddem, E. R., Yu, J., Bahna, F., Bimela, J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.005 · Cited by 519 · see citing works
REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
Baum, A., Ajithdoss, D., Copin, R., Zhou, A., Lanza, K., Negron, N., Ni, M., Wei, Y., Mohammadi, K., Musser, B., et al. (2020) · Science · doi:10.1126/science.abe2402 · Cited by 517 · see citing works
Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques
Deng, W., Bao, L., Liu, J., Xiao, C., Liu, J., Xue, J., Lv, Q., Qi, F., Gao, H., Yu, P., et al. (2020) · Science · doi:10.1126/science.abc5343 · Cited by 440 · see citing works
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine
Wu, K., Werner, A. P., Koch, M., Choi, A., Narayanan, E., Stewart-Jones, G. B. E., Colpitts, T., Bennett, H., Boyoglu-Barnum, S., Shi, W., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102179 · Cited by 409 · see citing works
Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation
Seydoux, E., Homad, L. J., MacCamy, A. J., Parks, K. R., Hurlburt, N. K., Jennewein, M. F., Akins, N. R., Stuart, A. B., Wan, Y.-H., Feng, J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.001 · Cited by 364 · cited 22× · see citing works
“As a consequence, several mAbs that potently neutralize SARS CoV-2 fail to bind SARS-CoV-1 (16, 22-24).”
BackgroundMethodInfluentialSelf-citation
Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection
Song, G., He, W.-T., Callaghan, S., Anzanello, F., Huang, D., Ricketts, J., Torres, J. L., Beutler, N., Peng, L., Vargas, S., et al. (2020) · doi:10.1101/2020.09.22.308965 · Cited by 285 · cited 1× · see citing works
“Neutralizing against other region of the viral spike have also been identified (24, 33, 38-42).”
Background
Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination
Horton, H., Thomas, E. P., Stucky, J., Frank, I., Moodie, Z., Huang, Y., Chiu, Y.-L., McElrath, M. J., & Rosa, S. C. D. (2007) · Journal of Immunological Methods · doi:10.1016/j.jim.2007.03.002 · Cited by 260 · see citing works
Self-citation
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy
Du, S., Cao, Y., Zhu, Q.-Y., Yu, P., Qi, F.-F., Wang, G., Du, X., Bao, L., Deng, W., Zhu, H., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.035 · Cited by 249 · see citing works
COVID-19 and the Path to Immunity
Stephens, D. S., & McElrath, M. J. (2020) · JAMA · doi:10.1001/jama.2020.16656 · Cited by 217 · see citing works
Self-citation
Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2
O'Toole, Á., Hill, V., Pybus, O. G., Watts, A., Bogoch, I. I., Khan, K., Messina, J. P., The COVID-19 Genomics UK (COG-UK) consortium, Network for Genomic Surveillance in South Africa (NGS-SA), Brazil-UK CADDE Genomic Network, et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16661.1 · Cited by 192 · see citing works
An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus
Snijder, J., Ortego, M. S., Weidle, C., Stuart, A. B., Gray, M. D., McElrath, M. J., Pancera, M., Veesler, D., & McGuire, A. T. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.026 · Cited by 140 · see citing works
Self-citation
Evidence for adaptive evolution in the receptor-binding domain of seasonal coronaviruses OC43 and 229e
Kistler, K. E., & Bedford, T. (2021) · eLife · doi:10.7554/elife.64509 · Cited by 94 · see citing works
Developing a SARS-CoV-2 Vaccine at Warp Speed
O’Callaghan, K. P., Blatz, A. M., & Offit, P. A. (2020) · JAMA · doi:10.1001/jama.2020.12190 · Cited by 82 · see citing works
COVID-19 Outbreak at an Overnight Summer School Retreat ― Wisconsin, July–August 2020
Pray, I. W., Gibbons-Burgener, S. N., Rosenberg, A. Z., Cole, D., Borenstein, S., Bateman, A., Pevzner, E., & Westergaard, R. P. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6943a4 · Cited by 53 · see citing works
OMIP‐056: Evaluation of Human Conventional T Cells, Donor‐Unrestricted T Cells, and NK Cells Including Memory Phenotype by Intracellular Cytokine Staining
Dintwe, O., Rohith, S., Schwedhelm, K. V., et al. (2019) · Cytometry Part A · doi:10.1002/cyto.a.23753 · Cited by 21 · see citing works

Flagged first, then by citations

Research works printed but not linked: 33

[9]Addetia A., Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. Journal of clinical microbiology 58, (2020). PMC7587101 32826322
[17]Zost S. J., Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443– 449 (2020). 32668443 PMC7584396
[20]Schafer A., Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. The Journal of experimental medicine 218, e20201993 (2021). 33211088 PMC7673958
[21]Suthar M. S., Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. Cell reports. Medicine 1, 100040 (2020). 32835303 PMC7276302
[23]Robbiani D. F., Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437– 442 (2020). 32555388 PMC7442695
[26]Rodda L. B., Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. Cell 184, 169– 183.e117 (2021). 33296701 PMC7682481
[27]Gaebler C., Evolution of antibody immunity to SARS-CoV-2. Nature, doi: 10.1038/s41586-41021-03207-w (2021). PMC8221082 33461210 · DOI
[29]Muecksch F., Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. The Journal of infectious diseases 223, 389– 398 (2021). 33140086 PMC7665595
[31]Steffen T. L., The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera. bioRxiv, 2020.2008.2021.261727 (2020).
[32]Barnes C. O., Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell 182, 828– 842 e816 (2020). 32645326 PMC7311918
[37]Greaney A. J., Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell host & microbe 29, 44– 57.e49 (2021). 33259788 PMC7676316
[42]Wang C., Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein. bioRxiv, 2020.2010.2020.346916 (2020).
[45]Corbett K. S., SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567– 571 (2020). 32756549 PMC7581537
[47]Vogel A. B., A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates. bioRxiv, 2020.2009.2008.280818 (2020).
[49]Walsh E. E., Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. The New England journal of medicine 383, 2439– 2450 (2020). 33053279 PMC7583697
[50]Rambaut A. (virological.org, 2020), vol. 2021.
[53]Davies N. G., Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England. medRxiv, 2020.2012.2024.20248822 (2020).
[57]Chan K. K., Tan T. J. C., Narayanan K. K., Procko E., An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants. bioRxiv, 2020.2010.2018.344622 (2020). PMC7888922 33597251
[58]Starr T. N., Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science 371, 850– 854 (2021). 33495308 PMC7963219
[59]Zhang L., SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nature communications 11, 6013 (2020). PMC7693302 33243994
[60]Zhou B., SARS-CoV-2 spike D614G change enhances replication and transmission. Nature, 10.1038/s41586-41021-03361-41581 (2021). 33636719 · DOI
[61]Liu Z., Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. bioRxiv, 2020.2011.2006.372037 (2020).
[64]Weisblum Y., Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife 9, e61312 (2020). 33112236 PMC7723407
[66]Wang P., Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. bioRxiv, 2021.2001.2025.428137 (2021).
[67]Graham C., Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike. bioRxiv, 2021.2002.2003.429355 (2021).
[68]Shen X., SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. bioRxiv, 2021.2001.2027.428516 (2021). PMC7934674 33705729
[69]Wibmer C. K., SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nature medicine, doi: 10.1038/s41591-41021-01285-x (2021). 33654292 · DOI
[70]Wang Z., mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature, doi: 10.1038/s41586-41021-03324-41586 (2021). PMC8503938 33567448 · DOI
[73]Yuan M., Structural basis of a shared antibody response to SARS-CoV-2. Science 369, 1119– 1123 (2020). 32661058 PMC7402627
[74]Wu N. C., An Alternative Binding Mode of IGHV3–53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. Cell reports 33, 108274 (2020). 33027617 PMC7522650
[78]Hurlburt N. K., Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. Nature communications 11, 5413 (2020). PMC7591918 33110068
[81]Liu Y., Neutralizing Activity of BNT162b2-Elicited Serum - Preliminary Report. The New England journal of medicine, doi: 10.1056/NEJMc2102017 (2021). PMC7944950 33684280 · DOI · Paper page
[87]Hsieh C. L., Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501– 1505 (2020). 32703906 PMC7402631

Sorted by citations

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection
Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D., et al. (2021) · doi:10.1101/2021.12.08.21267417 · Cited by 1,333 · see citing works
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
Wang, Z., Muecksch, F., Schaefer-Babajew, D., Finkin, S., Viant, C., Gaebler, C., Hoffmann, H. H., Barnes, C. O., Cipolla, M., Ramos, V., et al. (2021) · Nature · doi:10.1038/s41586-021-03696-9 · Cited by 721 · see citing works
Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination
Goel, R. R., Apostolidis, S. A., Painter, M. M., Mathew, D., Pattekar, A., Kuthuru, O., Gouma, S., Hicks, P., Meng, W., Rosenfeld, A. M., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abi6950 · Cited by 655 · see citing works
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Kent, S. J., Triccas, J. A., Khoury, D. S., & Davenport, M. P. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00267-6 · Cited by 590 · see citing works
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Yuan, M., Huang, D., Lee, C.-C. D., Wu, N. C., Jackson, A. M., Zhu, X., Liu, H., Peng, L., van Gils, M. J., Sanders, R. W., et al. (2021) · doi:10.1101/2021.02.16.430500 · Cited by 364 · see citing works
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Park, Y.-J., Pinto, D., Walls, A. C., Liu, Z., De Marco, A., Benigni, F., Zatta, F., Silacci-Fregni, C., Bassi, J., Sprouse, K. R., et al. (2022) · doi:10.1101/2022.05.08.491108 · Cited by 251 · see citing works

Authors: Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L. J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M. F., MacCamy, A. J., Feng, J., Mize, G., De Rosa, S. C., Finzi, A., Lemos, M. P., Cohen, K. W., Moodie, Z., McElrath, M. J., & McGuire, A. T.
Affiliations: University of Washington (US)
Fred Hutch Cancer Center (US)
Centre Hospitalier de l’Université de Montréal (CA)
Corresponding author: Stamatatos, Leonidas
McElrath, M. Juliana
McGuire, Andrew T.
ORCID: Stamatatos, Leonidas
Czartoski, Julie
Wan, Yu-Hsin
Homad, Leah J.
Rubin, Vanessa
Glantz, Hayley
Neradilek, Moni
Seydoux, Emilie
Jennewein, Madeleine F.
MacCamy, Anna J.
Feng, Junli
Mize, Gregory
Finzi, Andrés
Lemos, Maria P.
Cohen, Kristen W.
Moodie, Zoe
McElrath, M. Juliana
McGuire, Andrew T.
Venue: Science
Publisher: openRxiv
Published: 2021-02-08
Volume: 372
Issue: 6549
Pages: 1413-1418
ISSN: 0036-8075 (ISSN-L)
DOI: 10.1101/2021.02.05.21251182
PMC: PMC7987032
OpenAlex: W3136570200
Cited by: 559
References: 55
Citations by year: 2026: 14 · 2025: 35 · 2024: 49 · 2023: 72 · 2022: 212 · 2021: 176
FWCI: 40.19
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
Locations: Science (publishedVersion, cc-by)
medRxiv (acceptedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
PubMed Central (submittedVersion, cc-by-nc-nd)
Funders: Paul G. Allen Family Foundation
Fred Hutchinson Cancer Research Center (UM1 AI068618)
National Institute of Allergy and Infectious Diseases (COVID-19, AI-068618, UM1A057266-S1, AI069481, UM1AI068618, UM1AI068635, UM1AI069481, U19AI057266)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords: mRNA vaccines, SARS-CoV-2, booster vaccination, B.1.351 variant, reinfection protection, memory B cells, antibody neutralization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Record

About these checks